What is the translation of " SOFOSBUVIR " in English?

• sofosbuvir

Examples of using Sofosbuvir in Chinese and their translations into English

MyHep所有药物都是sofosbuvir和velpatasvir的组合。
MyHep All medication is a combination of sofosbuvir and velpatasvir.

Sofosbuvir(PSI-7977)是HCVRNA复制抑制剂，EC50为92nM。
Sofosbuvir(PSI-7977) is an HCV RNA replication inhibitor with an EC50 of 92 nM.

该药物在与sofosbuvir组合的短短6周内显示出100％的治愈率。
The drug has shown a 100% cure rate in as little as 6 weeks in combination with sofosbuvir.

在基因型2和3HCV感染中，sofosbuvir可与达卡他韦联合使用。
In genotype 2 and 3 HCV infections, sofosbuvir can be used in combination with daclatasvir.

Ledipasvir和sofosbuvir是2种丙型肝炎病毒（HCV）抗病毒药物的组合。
Ledipasvir& Sofosbuvir is a combination of 2 hepatitis C virus(HCV) antiviral agents.

所有的20名患者服用了6周的sofosbuvir和ledipasvir没有利巴韦林的药物。
All 20 patients completed six weeks of Sofosbuvir and Ledipasvir without Ribavirin.

Ledipasvir和sofosbuvir是2种丙型肝炎病毒（HCV）抗病毒药物的组合。
Ledipasvir and sofosbuvir is a combination of 2 hepatitis C virus(HCV) antiviral agents.

NS5B核苷聚合酶抑制剂sofosbuvir具有最高的耐药屏障[82]。
The NS5B nucleoside polymerase inhibitor sofosbuvir has the highest barrier to resistance[82].

Sofosbuvir（SOF）在发展中国家很容易获得，剂量为400mg/天。
Sofosbuvir(SOF), which is easily available in the developing world, is taken as a 400-mg tablet once daily.

不建议HARVONI与其他含sofosbuvir(SOVALDI®)产品使用。
Patients should not take Harvoni with other products that contain sofosbuvir(e.g. Sovaldi).

Sofosbuvir在药物的核苷酸类似物家族中并且通过阻断丙型肝炎NS5B蛋白起作用。
Sofosbuvir is in the nucleotide analog family of medication and works by blocking the hepatitis C NS5B protein.

岁的HanyTawfik是私人股权专家，他在2014年是第一位接受sofosbuvir的埃及人。
Asked Hany Tawfik, 66, a private equity specialist who in 2014 was the first Egyptian to receive sofosbuvir.

FDA批准simeprevir联合sofosbuvir用于治疗基因型1型的HCV感染.
Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection.

Ledipasvir和sofosbuvir是药物转运蛋白P-gp和BCRP的底物而GS-331007不是。
Sofosbuvir is a substrate of drug transporter P-gp and breast cancer resistance protein(BCRP) while GS-331007 is not.

这些最新报告在2011年底在FDA批准了两种口服HCV药物：simeprevir（Olysio）和sofosbuvir（Sovaldi）。
In late 2013, two new HCV therapies were approved by the FDA, simeprevir(Olysio) and sofosbuvir(Sovaldi)1.

Sofosbuvir（Sovaldi）在2013年获得FDA批准，是第一种被认为无干扰素安全有效的药物。
Sofosbuvir(Sovaldi) received FDA approval in 2013, and was the first drug deemed safe and effective without interferon.

吉利德的sovaldi的主要成分为sofosbuvir，harvoni则是sofosbuvir和另一个化合物ledipasvir组合。
Sovaldi is based on the compound sofosbuvir, while Harvoni combines sofosbuvir with the compound ledipasvir.

告诉你的医生或牙医你接受任何医疗或牙科护理，紧急护理或手术之前服用ledipasvir和sofosbuvir。
Tell your doctor or dentist that you take Ledipasvir& Sofosbuvir before you receive any medical or dental care, emergency care, or surgery.

而为期12周的索华迪（Sofosbuvir）治疗，就是未涵盖在基本保险内的医治丙型肝炎的方案之一，费用为69,600元人民币（约9,700美元）。
A 12-week Sofosbuvir course, one of the treatments not covered by primary insurance, costs 69,600 yuan($ 9700 USD).

ASTRAL-3临床试验报道，基因3型患者予sofosbuvir+velpatasvir联合治疗12周后，SVR12为95%[57]。
The ASTRAL-3 trial reported an SVR 12 of 95% in genotype 3 patients treated with sofosbuvir+ velpatasvir for 12 weeks[57].

HARVONI是一种两药固定剂量复方产品，在单一片中含90mgledipasvir和400mgsofosbuvir。
Harvoni is a two-drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet.

已经证明其他药物，如波普瑞韦，特拉匹韦和sofosbuvir可以提高这种治愈率，尽管这些药物都会带来额外的副作用。
Other drugs, such as boceprevir, telaprevir and sofosbuvir, have been shown to improve this cure rate, though all carry additional side effects.

最近被FDA批准的全基因型复合制剂之一，商品名为Epclusa，包含sofosbuvir+velpatasvir[55]。
One of the most recent FDA-approved pan-genotype combinations, available under the trade name Epclusa, contains sofosbuvir+ velpatasvir[55].

我们已经能够获得强大的市场善意，作为一个值得信赖的组织，为我们的客户提供SofihepSofosbuvir400mg片剂。
We have been able to attain strong market goodwill as a trusted organization engaged in offering our clients Sovihep Sofosbuvir 400 mg Tablets.

Sofosbuvir被合理地容忍了：不良事件是常见的(81%)，但严重的不良事件(17%)和治疗不连续性(8%)是不常见的。
Sofosbuvir was reasonably well tolerated: adverse events were common(81%), but serious adverse events(17%) and treatment discontinuations(8%) were uncommon.

DNDi展开STORM-C-1开放标签试验以评估候选药物ravidasvir与sofosbuvir联用的疗效、安全性、耐药性和药物动力学。
DNDi conducted the STORM-C-1 open label trial to assess the efficacy, safety, tolerance and pharmacokinetics of the drug candidate ravidasvir combined with sofosbuvir.

Sofosbuvir是一种针对丙肝病毒的有效的直接抗病毒药物治疗，但是对潜在的肾脏毒性的担忧已经增加，尤其是在CKD患者身上。
Sofosbuvir is a potent direct-acting antiviral therapy against HCV, but concerns about potential kidney toxicity have been raised, particularly in patients with CKD.

年4月7日，美国食品和药物管理局批准了Sovaldi（sofosbuvir）和Harvoni（ledipasvir和sofosbuvir）在12至17岁儿童中治疗丙型肝炎病毒（HCV）的补充申请。
The US Food and Drug Administration on April 7 approved supplemental applications for sofosbuvir and ledipasvir and sofosbuvir(Harvoni) to treat HCV in children ages 12 to 17.